PDCD1 and non-small cell lung carcinoma: Similarly, Programmed Cell Death Protein 1 (PD-1) inhibitors and their ligand PD-L1 have demonstrated efficacy in various cancers, including NSCLC, renal cell carcinoma, and head and neck cancer, by reactivating exhausted T cells [13,14].